Great company... with 350M$ in cash and 200M$ in debt it is well positioned in a great way for expansion... it will continue so... at least double itself in the next half year to 1 year...
Phase 3 Top results and a promising techlogy... right now price is a bargain at 7$... i predict an amazing future for this company and it's new technology...
With Dr. Philip Frost as chairman and owner of 25% of this little Israeli company, also chosen as 1 of 3 top performing bio-tech company for 2010... BUY BUY BUY
Find Winning Stocks Quickly with Research Wizard, a powerful desktop software program. Start with easy-to-use pre-loaded strategies, then develop your own. Backtest against years of historical data to see how your approach works in any market. Start a Free Trial Today >>
Ride Momentum Stocks to Quick Gains!
The market is finally breaking out, creating the perfectd wave for investing in momentum stocks. Zacks is the king of fundamental analysis, but this service also uses technical indicators for the best possible timing. Click here to learn more >>.
Zacks Top Ten Stocks for 2011 are now available! This 10-stock portfolio is a well-balanced mix of aggressive and conservative, large and small cap, growth and value. Buy them. Hold them. Watch your gains add up
Stock screening and chart patterns expert, Kevin Matras, combs through the best Zacks stock-picking strategies averaging +60% yearly gains to find stocks with charts showing they are ready to skyrocket. Chart Patterns Trader >>
No Stocks are Harder to Find, or More Worth the Effort.
They have the greatest potential for quick gains, but they're also the most difficult to find and time correctly. Now Zacks has perfected a system for identifying and profiting from turnaround stocks just as they begin a powerful rebound.
Learn more here >>.
With recent purchases and less and less depend on copaxon, Teva will be back on track in 2012.
Target price 45-50$
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 1 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment